While no outcome data is yet available from subgroup analyses of PAM50 intrinsic molecular subtypes in these studies, the CheckMate 7FL trial demonstrated that adding the anti-PD-1 agent nivolumab to neoadjuvant chemotherapy significantly improved pathological complete response rates in high-risk ERpHER2n breast cancer, particularly in tumors with high stromal TIL levels and/or PD-L1 positivity. Here, CD274 is linked to breast cancer.